key: cord-0772367-613t21n5
authors: Meziani, Lydia; Robert, Charlotte; Classe, Marion; Da Costa, Bruno; Mondini, Michele; Clémenson, Céline; Alfaro, Alexia; Mordant, Pierre; Ammari, Samy; Goffic, Ronan Le; Deutsch, Eric
title: Low doses of radiation increase the immunosuppressive profile of lung macrophages during viral infection and pneumonia
date: 2021-03-13
journal: Int J Radiat Oncol Biol Phys
DOI: 10.1016/j.ijrobp.2021.03.022
sha: 7229045b7cdfdc3ee4278742b414de87799a2d08
doc_id: 772367
cord_uid: 613t21n5

Purpose severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in patients with severe COVID-19. Recently, early clinical data reported the feasibility of low doses of radiation therapy (RT) in the treatment of ARDS in patients with severe COVID-19. However, the involved mechanisms remained unknown. Methods and materials here, we used airways-instilled lipopolysaccharide (LPS) and influenza virus (H1N1) as murine models of pneumonia, and Toll- like receptor (TLR)-3 stimulation in human lung macrophages. Results low doses RT (0.5-1Gy) decreased LPS induced pneumonia, and increased the percentage of Nerve- and Airway- associated Macrophages (NAMs) producing IL-10. During H1N1 viral infection, we observed decreased lung tissue damage and immune cell infiltration in irradiated animals. Low doses RT increased IL-10 production by infiltrating immune cells into the lung. Irradiation of TLR-3 ligand-stimulated human lung macrophages ex vivo increased IL-10 secretion and decreased IFNγ production in the culture supernatant. The percentage of human lung macrophages producing IL-6 was also decreased. Conclusion our data highlight one of the mechanisms by which low doses RT regulate lung inflammation and skew lung macrophages towards an anti-inflammatory profile. These data provide a preclinical mechanistic support to clinical trials evaluating low doses RT, as for COVID-19-induced ARDS.

The COVID-19 pandemic is responsible for more than 1.8 million deaths and 85.8 million cases worldwide as of January 5, 2021. The responsible agent, SARS-CoV-2, is an enveloped RNA virus of the Coronaviridae virus family. Human-to-human transmission occurs through respiratory droplets or contaminated surfaces [1] . The average incubation period is 5 days, with a range of 1 to 14 days. Most patients present mild respiratory tract infections, most commonly characterized by fever (82%) and cough (81%). Severe pneumonia and acute respiratory distress syndrome (ARDS) have been described in 14% of the reported cases, and the overall mortality is around 1-2% [2] . Current therapeutic approaches involve mechanical ventilation, acute supportive care management of organ failure, steroids and antiviral therapies such as remdesivir.

Growing information suggests that patients with severe COVID-19 have a marked inflammatory state characterized by a cytokine storm syndrome similar to that seen in severe influenza cases [3] , and high levels of both calprotectin and myelopoiesis [4] .

Chest irradiation at low dose has been used successfully in the past to treat pneumonia, especially before the onset of effective antimicrobial agents. The estimation of the radiation doses absorbed by the lungs during orthovoltage irradiation techniques rendered complex at that time. Clinical reports suggest an early improvement of breathing difficulties within hours and a reduction of mortality [5] [6] [7] . Currently, several clinical trials are underway (referenced on clinicaltrial.gov) and some studies, even if in small cohorts, confirmed the efficacy of low doses of RT in the treatment of ARDS in patients with severe COVID-19 [8] [9] [10] [11] . However, the involved mechanisms remain unknown and the use of chest radiation therapy (RT) for COVID patients has been the subject of a vivid scientific controversy. Amongst the authors, for and against arguments, is the absence of proof of concept as well as the intrinsic risk that radiation induces lung damage and boosts viral expansion after RT.

RT exerts well-known anti-inflammatory properties when used at doses up to 1Gy while producing pro-inflammatory effects at higher doses [12] , highlighting the complexity of the immunological mechanisms and the interrelationship between ionizing radiation (IR) and

inflammation.

Pulmonary macrophages have been implicated in maintaining lung homeostasis by immune surveillance and clearance of dead cells, debris, and invading pathogens. The lung harbors two distinct populations of macrophages, alveolar macrophages (AMs) and interstitial macrophages (IMs) [13, 14] . AMs are located in alveolar space and seem to play a direct antiviral role since AM depletion yields higher viral loads. IMs are located in the interstitium, along with dendritic cells and lymphocytes. Recently, a new IM subpopulation of Nerve-and Airway-associated Macrophages (NAMs), have been characterized in mice [15] . NAMs are distinct from other lung-resident macrophage subsets and highly express immunoregulatory genes. NAMs proliferate robustly after influenza infection and activation with the polyinosinic:polycytidylic acid [Poly(I:C)], and in their absence the inflammatory response is augmented, resulting in excessive production of inflammatory cytokines and innate immune cell infiltration. NAMs function is to maintain immune and tissue homeostasis, and regulate infection-induced inflammation through the secretion of immunosuppressive factors such as IL-10. Viral infection in the absence of NAMs is associated with an excess of proinflammatory cytokines and chemokines such as IL-6, CCL2, CCL3, and CCL5 eventually leading to massive lung damage and death [15] . Interestingly, potential pathological roles of macrophages during SARS-CoV-2 infection have been described [16] .

Irradiation has a direct effect on macrophage activation, depending on time, dose, and subpopulations. In the tumor stroma, high doses of IR (> 8Gy) promote anti-inflammatory activity of macrophages [17] and low doses (< 2Gy) alone or combined with immunotherapy induce proinflammatory activity of macrophages [18, 19] . Within the lung, irradiation at high dose (16Gy) affects the phenotype of alveolar and interstitial macrophages differently, resulting in distinct local cytokine and chemokine microenvironments in the tissue and alveoli.

Interestingly, there is a difference between lung sub compartments in response to fibrogenic irradiation dose (16Gy) with an immune response first in the parenchyma, then in the alveolar compartment [20] .

In the present study, using Lipopolysaccharide (LPS), influenza A PR8 virus (H1N1) or Toll-like receptor 3 (TLR3) ligand Poly(I:C) as inductors of inflammation [21] , and low doses of RT as a potential treatment, we investigated whether RT could be involved in counteracting lung inflammation through IL-10 production.

All patients signed an informed consent allowing the use of their surgical specimen for research purposes. The database was declared to the National Board for Informatics and Freedom (authorization #XXXXXXX) and to the National Institute for Health Data (authorization #XXXXXXXXXXXX). Immediately after anatomical lung resection for lung cancer (n =3) or benign disease (n=1), a 2cm wide peripheral wedge of macroscopically normal lung parenchyma was harvested on the surgical specimen and kept in sterile saline solution at 4°C.

Animal procedures were performed according to protocols approved by the Ethical Committee XXXX XX and in accordance with recommendations for the proper use and care of laboratory animals. For the pneumonia model, female C57BL/6 mice (10 weeks old) were purchased from Janvier Laboratories.

For the pneumonia model, mice were anesthetized (isoflurane), and either LPS (O55:B5) or Poly(I:C) in 50 µl sterile phosphate-buffered saline (PBS), or PBS alone (as control), were administered intratracheally. Mice received two sublethal doses (100 µg and 50 µg) of LPS or (100 µg and 50 µg) Poly(I:C) with a 24-hour rest period between each administration.

Mice received a lethal dose (500PFU) of influenza virus (A/Puerto Rico/8/1934 (H1N1)), in 50mL of PBS by intranasal instillation.

Six hours after the second administration of LPS or Poly(I:C), the mice were immobilized by anesthesia (2% isoflurane) and locally irradiated at the thorax using a Varian Tube NDI 226 (Xray machine; 250 kV, tube current:15 mA, beam filter: 0.2 mm Cu), with a dose rate of 1.08

Gy·min−1. A single dose of 0.5 or 1 Gy was locally delivered to the whole thorax.

A single dose of 10mg/kg of dexamethasone (Dexamethasone Mylan 4 mg/1ml, solution for injection, lot n°200147, Mylan) was administered to the mice by intraperitoneal injection.

Mice underwent CT scan at lung level. During scanning, mice were immobilized by anesthesia (2% isoflurane). ImageJ software was used to quantify lung density on axial slices.

After animal euthanasia, the trachea was cannulated and secured using a silk suture. Cold PBS (500mL) was delivered and retrieved through the cannula. The lavage was repeated three times.

BAL fluid was used for virus titration.

BAL fluids viral titers were determined by standard plaque assay using Madin Darby canine kidney (MDCK) cells. Briefly, confluent monolayers of MDCK cells were infected with serially diluted BAL fluids. Infected monolayers were then covered with semisolid overlay medium (Avicel). 48 hours post-infection, cells were fixed using paraformaldehyde and lysis plaques were counted after crystal violet counterstaining.

Mouse lungs were fixed in 4% buffered ParaFormaldehye (PFA), paraffin embedded and then cut into 4m sections. Lung sections were stained with hematoxylin-eosin-saffron (HES) and digitized using a slide scanner (Olympus VS120). Histopathological analysis was performed by a Pathologist, using a semi-quantitative scoring for the following parameters: 

Human and mouse lung tissues were digested using the Tumor Dissociation Kit (Miltenyi Biotec) for 30 minutes at 37°C and 1,500 rpm. The cells from the digested lung tissues were filtered using cell strainers (70 µm, Miltenyi Biotech) and used for subsequent experiments.

After washing with PBS and centrifugation (300 g, 4°C, 5 minutes), the human lung cells were suspended and cultured in DMEM-F12 supplemented with both fetal bovine serum (FBS; 10%) and penicillin/streptomycin (1%). Human lung cells were incubated in the indicated medium at 37°C and 5% CO2 for 30 minutes. Then, the adherent cells (macrophages and monocytes) were washed using PBS, and the nonadherent cells were discarded. The adherent cells were incubated in fresh medium (DMEM-F12 containing 10% FBS and 1% penicillin/streptomycin) and stimulated with either Poly(I:C) at 1ug/mL or PBS (as control). Six hours after stimulation with the Poly(I:C), macrophages were irradiated using X-RAD320 (X-ray machine; 320 Kev, 4 mA) at a single dose of 0.5 or 1 Gy.

For cultured human lung macrophages staining: anti-CD169 (7-239) and anti-CD11c (REA618, Miltenyi Biotec) were used for membrane staining. Anti-IL-10 (REA842) and anti-IL-6 (REA1037, Miltenyi Biotec) were used for intracellular staining. For intracellular staining, cells were pre-activated before membrane staining using Cell Activation Cocktail (with Brefeldin A, Biolegend) for 2 hours at 37°C. Samples were acquired on an LSR Fortessa X20 (BD, Franklin Lakes, NJ) with FACSDiva software, and data were analyzed with FlowJo 10.0.7 software (Tree Star, Inc., Ashland, OR).

Cytokine concentrations in culture supernatants from in vitro-activated human macrophage samples were profiled. The proteins in the supernatant were diluted to 4 mg/mL and analyzed using MACSplex Human cytokine (Miltenyi Biotec) and data were analyzed with FlowLogic 7.3 software.

Statistical analysis was performed using GraphPad Prism 7. One-way ANOVA was used to detect differences among multiple treatment groups. A p value equal to or less than 0.05 was considered significant (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Data are expressed as the mean±standard error of mean (SEM).

To investigate whether low doses of RT protect mice from lung inflammation, we treated mice with sublethal doses of LPS by intratracheal administration over two consecutive days. Six hours after the second intratracheal administration, mice were irradiated at the whole thorax at 0.5 or 1 Gy and underwent Computed tomography (CT) imaging at lung level at several time points after whole thorax irradiation. LPS administration significantly increased lung density at 96 hours (post administration of the first dose of LPS) compared to PBS control, suggesting the development of an inflammatory process in the lungs (Fig. 1A) . Interestingly, irradiated lungs at 1 Gy had a reduced lung density compared to the LPS group, suggesting that a low dose of 1 Gy protects mice from LPS-induced lung inflammation. Furthermore, histopathological analysis showed a decrease in parenchyma destruction (Fig. 1B) and a trend towards a reduced peribronchial infiltration in irradiated lungs at 1 Gy (Fig. 1C) .

NAMs act as a main player to counteract lung inflammation via IL-10 secretion 15. We therefore hypothesized that, in the preclinical LPS pneumonia model, low doses of RT could stimulate IL-10 secretion by NAMs. Our results showed that LPS-induced lung inflammation is associated with a trend towards an increased percentage of NAMs producing IL-10 ( Fig. 1D) .

Interestingly, low doses of RT further increased the percentage of NAMs producing IL-10 compared to the non-irradiated group. Using a Poly(I:C)-induced inflammation model, we confirmed that low doses of RT induced a greater increase of IL-10 + NAMs percentage compared to PBS control (Fig. 1E) .

To evaluate the effect of low doses of RT on a viral pneumonia model, we treated mice with a lethal dose of PR8 virus (a murine-adapted influenza strain) by intranasal instillation. Two days after the instillation, mice were irradiated at the whole thorax at 0.5, 1 Gy or/and treated with a single dose of dexamethasone. Histopathological analysis of the lung showed that, four days after viral infection, PR8 virus induced a significant increase in both emphysema/alveolar septum rupture and the thickening of the alveolar septum compared to the PBS group (Fig. 2, A and B) . Low doses of RT as well as dexamethasone decreased the emphysema/alveolar septum rupture (p=0.0001 for 0.5 Gy and p=0.06 for both 1 Gy and dexamethasone) and a slight, even if not-significant, reduction of the thickening of the alveolar septum was observed in low doses of RT and dexamethasone groups compared to the PR8 condition. At eight days post-infection, we observed a significant increase in both vascular congestion and red blood cell extravasation in the PR8 group compared to the PBS group (Fig. 2, C and D) . Interestingly, low doses of RT or dexamethasone did not exacerbate Figure 1A) . Altogether, our data showed that low doses of RT did not aggravate both tissue damages and inflammatory cell infiltration in the lungs during viral infection.

Flow cytometry analysis three days after PR8 infection showed that 0.5 Gy of RT, in contrast to dexamethasone treatment, induced a significant increase in the percent of NAMs producing IL-10 (Fig. 3A) . Low doses of RT combined with dexamethasone induced an upward trend in the percent of NAMs producing IL-10 when compared to dexamethasone alone (supplementary Fig. 1B) . The percent of NAMs producing both IFNand IL-6, significantly decreased after PR8 infection compared to the PBS group, and it was neither affected by low doses of RT nor dexamethasone (supplementary Fig. 2) . Similarly, low doses of RT induced an increase in the percent of both AMs and neutrophils producing IL-10 compared to the other group (Fig. 3, B and C). Low doses of RT combined with dexamethasone induced an increasing trend in the percent of both AMs and neutrophils producing IL-10 when compared to dexamethasone alone (supplementary Fig. 1B) . The percents of AMs and neutrophils producing IFNand IL-6 were not affected by the different treatments (supplementary Fig. 2 ). In agreement with data obtained with LPS and poly(I:C) models, our data clearly show that low doses of RT during viral infection stimulate murine NAMs (as well as alveolar macrophages and neutrophils) to produce IL-10.

We then aimed to confirm whether low doses of RT could stimulate human lung macrophages to produce IL-10 (Fig. 4A) . Sixteen hours after human macrophage irradiation, culture supernatants were analyzed for cytokine secretion and human macrophage activation was analyzed by flow cytometry. The quantification of the supernatants showed that low doses of RT decreased IFNsecretion and increased IL-10 secretion by Poly(I:C)-stimulated human lung macrophages compared to non-irradiated Poly(I:C)-stimulated ones (Fig. 4B) . The levels of IFN, TNF, IL-2 and IL-9 were not affected by the low doses of RT.

Subsequently, we performed flow cytometry analysis for human lung macrophages and observed an increase in the percentage of human lung macrophages producing IL-10 after low-dose irradiation of 0.5 Gy compared to other culture conditions (Fig. 4C) . Interestingly, the percentage of human lung macrophages producing IL-6 decreased after low-dose irradiation of 0.5 and 1 Gy compared to non-irradiated human lung macrophages (Fig. 4D) .

Finally, we evaluated the impact of low doses of RT on viral load in the lung. Four days after PR8 infection, broncho-alveolar lavage fluid from infected animals, were analyzed for the measurement of the viral titers (Fig. 5A) . Our results indicated that low doses of RT as well as dexamethasone treatment have no effect on virus levels in the lungs (Fig. 5B) .

In the present study, we described the role of low doses of RT in: 1-protecting mouse lungs from inflammation; 2-further stimulating the production of anti-inflammatory cytokine IL-10 by NAMs in vivo; and 3-counterbalancing the effect of the proinflammatory stimuli in vitro in human lung macrophages.

The effect of low doses of RT on bone marrow-derived macrophage phenotype and on macrophage cell lines (RAW264.7 and THP-1) has already been reported elsewhere.

Interestingly, low doses of RT (0.5 Gy) affects the bone marrow-derived macrophage phenotype, however, this strongly depends on the microenvironment [22] . Furthermore, a decrease in IL-1b secretion by macrophage cell lines after low doses of RT (0.5 and 0.7Gy) has been reported and LPS-induced TNF production was suppressed in 0.5 Gy-irradiated RAW264.7 [23, 24] . Accordingly, our results showed that human lung macrophages were affected by low doses of RT (0.5 and 1Gy) in vitro. Irradiated human lung macrophages decreased IFNproduction and increased IL-10 secretion. Furthermore, the percentage of human lung macrophages producing IL-10 increased after low doses of RT, while the percentage of human lung macrophages producing IL-6 decreased after exposure to inflammatory stimuli. Our data demonstrates that low doses of RT are involved in limiting the inflammatory response in favor of an anti-inflammatory response. In preclinical pneumonia models, tissue resident NAMs have been reported to robustly respond to inflammatory stimuli early during infection and to be the main negative regulators of inflammation in the lung via IL-10 production as a potential mechanism [15] . Similarly, our data confirmed the production of IL-10 by NAMs after Poly(I:C), LPS and PR8 influenza virus infection. Furthermore, we observed that a low dose of RT protects mice from lung inflammation, does not exacerbate lung tissue damages and decreases immune cell infiltration. Whether or not the same NAMs that have been described in mice exist in human lungs with the same immunosuppressive function is not yet defined. Our data from in vitro -cultured human lung macrophages are not sufficient to answer this question and further immunohistological/cytofluorimetric analyses of human lung tissue are required.

In pneumonia, several old clinical studies have reported the suggested improvement after low doses of RT [5] [6] [7] . However, after the onset of effective antimicrobial agents, the use of IR in the treatment of patients has been discontinued and the involved mechanism remained unknown. Following the excess death toll related to the COVID-19 pandemic, some radiation oncologists suggested the use of low doses of RT to treat COVID-19 patients suffering from ARDS [25] [26] [27] [28] [29] , even if this raised some criticism, [30] [31] [32] [33] given the uncertainties regarding a potential viral flare-up or an increase in lung tissue damage [34] . In the absence of preclinical data, the scientific community is puzzled between the risks associated with a whole lung irradiation (acute worsening of the patients, and the immediate intrinsic risk of ARDS) [34] .

Our present study is the first to propose a key role of low doses of RT in the management of pneumonia using preclinical models and suggests lung macrophage reprogramming into immunosuppressive profile as one of the mechanisms involved.

Thrombotic events in the lungs of COVID-19 patients following ARDS have been reported [35] .

Our results showed that PR8 influenza infection induced vessel congestion and obstruction, similar to what is observed in human COVID-19 lung infection. Interestingly, we show that low doses of RT do not worsen this phenomenon of obstructed vessels; on the contrary, there is a downward trend. Furthermore, AMs play a pivotal role in the antiviral defense during influenza virus pneumonia and their depletion induced viral expansion [15] . Our results obtained using PR8 influenza pneumonia model indicate that low doses of RT have no effect, neither on the AM population nor on viral expansion, suggesting that the use of low doses of RT would not negatively affect these parameters in viral pneumonias.

Our data show that low doses of RT decrease the tissue damages in the infected mice, and will contribute to define the optimal radiation dose to be used in the clinic, which is the minimal dose to induce a maximal impact on macrophage reprogramming without tissue damages, our data suggest that the 0.5-1Gy ranges should be considered clinically. In line with our data, several clinical studies including COVID-19 presenting pneumonia patients with advanced age or comorbidities reported an absence of acute toxicity after whole thorax low doses of RT [8, 10] . I n t h e s e clinical studies, the authors reported an improvement in the respiratory function of the patients in the hours following low doses of RT with a marked improvement on the CT scan around 7 days after RT. These observations are in line with the kinetics of our observations. In summary, in line with the recent clinical data, the present study suggests that a single low-dose chest irradiation could be an efficient strategy to resolve human lung inflammation in pneumonia. Low doses of RT induce human lung macrophage reprogramming, in particular the production of the immunosuppressive IL-10 cytokine and the suppression of the inflammatory signals (IFN), which could be one of the mechanisms by which low doses of RT protect from human pneumonia (Fig. 6) . Interestingly, IFN and TNF neutralizing treatment protect mice from both tissue damage and mortality during SARS-CoV-2 infection [36] .

Our study has several limitations including the absence of the SARS-CoV-2 mouse model due to a limited access to this model. Furthermore, Due to the difficult access to human samples, we have not be able to collect healthy human lung tissue in order to repeat experiment in Figure 4C and 4D.

Our experiments were performed using only female mice and it will be interesting to validate our data using male mice. Flow cytometry data showed that RT plus dexamethasone combination induced a similar effect as that of RT alone in terms of the absolute number of infiltrating immune cells and an upward trend in the production of the immunosuppressive IL-10 cytokine. These data do not seem to support a concomitant use of low doses of RT with dexamethasone to treat pneumonia. Nevertheless, clinical studies have been performed by treating COVID-19 patients whose clinical symptoms were progressing after dexamethasone treatment [10] . There is a need to conduct future preclinical studies evaluating sequential treatments of dexamethasone followed by low doses of RT to determine whether these treatments may be additive when separated over time.

On the other hand, it is important to note that low doses of RT exerted effects of amplitude similar, if not higher, than dexamethasone alone, suggesting that low doses of RT may be a therapeutic option, especially for patients not eligible to dexamethasone treatment.

Our data highlight the effect and good tolerance of low doses of RT on both human and murine macrophage reprogramming and the positive regulation of lung inflammation. Our findings are in agreement with the initial clinical data released from two out of the current 14 activated clinical trials worldwide evaluating chest RT for COVID-19 patients and contribute to justifying the use of RT in this very unusual non-cancer setting. Of note, the radiation doses used empirically in these clinical trials were not uniform; we do believe that carefully defining the lowest as possible effective dose is a major challenge at the heart of the current controversy and our data underscore the fact that doses 0.5-1 Gy are effective in reducing inflammation. These data provide a preclinical mechanist ic support to clinical t rials evaluat ing low doses of RT, as for COVID-19-induced ARDS. 

China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

COVID-19: consider cytokine storm syndromes and immunosuppression

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Radiation therapy of lobar pneumonia

Roentgen therapy of interstitial pneumonia

The effect of roentgen therapy on experimental virus pneumonia; on pneumonia produced in white mice by swine influenza virus

Low-Dose Whole-Lung Irradiation for COVID-19 Pneumonia: Short Course Results

Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day 7 Interim Analysis of a Registered Clinical Trial

Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with Coronavirus Disease 2019-Related Pneumonia

Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review

Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases

Tissue-resident macrophages

Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches

Identification of a nerve-associated, lung-resident interstitial macrophage subset with distinct localization and immunoregulatory properties

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy

Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophage and the septal fibroblast

Low-dose irradiation programs macrophage differentiation to an iNOS + /M1 phenotype that orchestrates effective T cell immunotherapy

CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages

Long-term activation of TLR3 by Poly(I:C) induces inflammation and impairs lung function in mice

Low-Dose Irradiation Differentially Impacts Macrophage Phenotype in Dependence of Fibroblast-Like Synoviocytes and Radiation Dose

Differential Effects of Irradiation with Carbon Ions and X-Rays on Macrophage Function

Low dose ionising radiation leads to a NF-κB dependent decreased secretion of active IL-1β by activated macrophages with a discontinuous dose-dependency

Is low dose radiation therapy a potential treatment for COVID-19 pneumonia?

Whole-lung Low Dose Irradiation for SARS-Cov2 Induced Pneumonia in the Geriatric Population: An Old Effective Treatment for a New Disease? Recommendation of the International Geriatric Radiotherapy Group

Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial

Low dose lung radiotherapy for COVID-19-related cytokine storm syndrome: Why not?

Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS)

Low dose radiation therapy for COVID-19 pneumonia: A doubleedged sword

Low-dose radiation as a treatment for COVID-19 pneumonia: A threat or real opportunity?

Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable

Is there any supportive evidence for low dose radiotherapy for COVID-19 pneumonia?

Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes